# A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

> **NCT04012255** · PHASE1 · TERMINATED · sponsor: **Novo Nordisk A/S** · enrollment: 29 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Semaglutide (administered by DV3396 pen)
- **DRUG:** Semaglutide (administered by PDS290 pen)

## Key facts

- **NCT ID:** NCT04012255
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-15
- **Primary completion:** 2019-08-30
- **Final completion:** 2019-10-22
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** The trial was terminated for strategic reasons.
- **Last updated:** 2019-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04012255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04012255, "A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04012255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*